receptors and enzymes

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/6

encourage image

There's no tags or description

Looks like no tags are added yet.

7 Terms

1
New cards

Name the four main receptor families and state their cellular locations.

  1. Ligand-gated ion channels (cell membrane, e.g., nicotinic acetylcholine receptor). 2. G protein-coupled receptors (GPCRs; cell membrane, e.g., dopamine receptors). 3. Kinase-linked / enzyme-linked receptors (cell membrane, e.g., insulin receptor). 4. Nuclear receptors (intracellular—cytosol or nucleus, e.g., steroid/oestrogen receptors).


2
New cards

Explain the activation mechanism and downstream signalling pathways of Receptor Tyrosine Kinases (RTKs).

Ligand binding (e.g., insulin, EGF, VEGF, IGF) induces receptor dimerization and activation of intracellular tyrosine kinase domains, leading to cross-phosphorylation of tyrosine residues. Phosphorylated tyrosines act as docking sites for intracellular signalling proteins, activating: 1. PLCγ (IP3/DAG/PKC). 2. The MAPK cascade. 3. PI-3 kinase (producing PIP3 -> Protein Kinase B [PKB]). These regulate transcription/translation to drive cell survival, proliferation, and growth, and are frequently mutated in cancer.

3
New cards

Give examples of biologic (monoclonal antibody) and small-molecule kinase inhibitor drugs targeting RTKs.

Biologics (monoclonal antibodies): Herceptin (trastuzumab; targets HER2 in breast cancer), Erbitux (cetuximab; targets EGFR in colon cancer), and Avastin (bevacizumab; targets VEGF in colon/NSCLC). Small-molecule inhibitors: Imatinib, Dasatinib, Nilotinib (target Abl/PDGFR/c-Kit in CML/GIST), Erlotinib and Gefitinib (target EGFR in NSCLC), and Sorafenib and Sunitinib (target VEGFR/PDGFR/FLT3/c-Kit in renal carcinoma/GIST).

4
New cards

Describe the cellular localisation, mechanism of action, and clinical drug examples for nuclear receptors.

Lipophilic ligands cross the plasma membrane and bind cytosolic receptors (e.g., steroid receptors like glucocorticoid receptor [GR] and oestrogen receptor [ER]) or nuclear receptors (e.g., thyroid receptors, PPAR, RAR, RXR, VDR). The ligand–receptor complex binds DNA promoter elements to alter gene transcription and protein synthesis (slow onset). Drug examples: Dexamethasone/Prednisolone (GR; inflammatory/immunological disorders), Tamoxifen/Raloxifene (ER; breast cancer), Fenofibrate (PPARα; dyslipidaemia), Pioglitazone (PPARγ; diabetes), Isotretinoin (RAR; acne/leukaemia), Bexarotene (RXR), and Calcitriol (VDR; osteoporosis).

5
New cards

Compare competitive, non-competitive (allosteric), false-substrate, reversible, and irreversible enzyme inhibition.

  1. Competitive inhibitor: mimics substrate at the active site without being converted; reversible—increasing substrate concentration overcomes inhibition (apparent Km increases, Vmax is unchanged). 2. False substrate: mimics substrate and is converted into an abnormal product. 3. Non-competitive (allosteric) inhibitor: binds an allosteric site to reduce catalytic activity (Vmax decreases). 4. Irreversible inhibitor: binds tightly or covalently modifies the enzyme, producing a long-lasting clinical effect until new enzyme is synthesized.
6
New cards

Compare the mechanisms of action and clinical effects of Aspirin versus Ibuprofen on cyclooxygenase (COX-1/COX-2).

Both inhibit COX-1 and COX-2, blocking conversion of arachidonic acid into thromboxane A2 (TxA2) and prostaglandins (PGI2, PGD2, PGE2, PGF2). Aspirin (acetylsalicylic acid) is an irreversible covalent inhibitor that acetylates COX—used at low doses as an anti-thrombotic (blocks platelet COX-1 TxA2 synthesis) and high doses as an analgesic/anti-inflammatory (blocks COX-2 prostanoids). Ibuprofen is a competitive, reversible inhibitor of COX-1 and COX-2 used for pain, fever, and inflammation.

7
New cards

Define a prodrug and give two clinical examples activated by enzymes.

A prodrug is an inactive precursor molecule that requires enzymatic conversion in the body into its active pharmacological form. Examples: 1. Cortisone -> converted to active hydrocortisone (anti-inflammatory). 2. Clopidogrel -> converted to its active metabolite (inhibits platelet aggregation).